Journal of Nucleic Acids [55] A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” New England Journal of Medicine, vol. 355, no. 24, pp. 2542– 2550, 2006. [56] H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, ﬂuorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. [57] R. Karni, E. de Stanchina, S. W. Lowe, R. Sinha, D. Mu, and A. R. Krainer, “The gene encoding the splicing factor SF2/ASF is a proto-oncogene,” Nature Structural and Molecular Biology, vol. 14, no. 3, pp. 185–193, 2007. [58] D. G. Nowak, J. Woolard, E. M. Amin et al., “Expression of pro- and anti-angiogenic isoforms of VEGF is diﬀerentially regulated by splicing and growth factors,” Journal of Cell Science, vol. 121, no. 20, pp. 3487–3495, 2008. [59] T. Ezponda, M. J. Pajares, J. Agorreta et al., “The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression,” Clinical Cancer Research, vol. 16, no. 16, pp. 4113–4125, 2010. [60] D. G. Nowak, E. M. Amin, E. S. Rennel et al., “Regulation of Vascular Endothelial Growth Factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeu- tic strategy for angiogenesis,” Journal of Biological Chemistry, vol. 285, no. 8, pp. 5532–5540, 2010. [61] S. Schwartz, E. Meshorer, and G. Ast, “Chromatin organi- zation marks exon-intron structure,” Nature Structural and Molecular Biology, vol. 16, no. 9, pp. 990–995, 2009. [62] D. Auboeuf, D. H. Dowhan, X. Li et al., “CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing,” Molecular and Cellular Biol- ogy, vol. 24, no. 1, pp. 442–453, 2004. [63] C. Puppin, N. Passon, A. Franzoni, D. Russo, and G. Damante, “Histone deacetylase inhibitors control the transcription and alternative splicing of prohibitin in thyroid tumor cells,” Oncology Reports, vol. 25, no. 2, pp. 393–397, 2011. [64] J. Ciura and P. P. Jagodzinski, “Butyrate increases the for- mation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells,” Molecular Biology Reports, vol. 37, no. 8, pp. 3729–3734, 2010. [65] M. Peiris-Pages, S. J. Harper, D. O. Bates, and P. Ramani, “Bal- ance of pro-versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth,” Journal of Pathology, vol. 222, no. 2, pp. 138–147, 2010. 7